Search results
Izokibep Enthesitis Benefit Lacking in Phase 2b/3 PsA Trial
Medscape· 10 hours agoThe primary efficacy endpoint was met, but the novel small molecule therapeutic did not reduce...
Pharma giant's data breach exposes patients' sensitive information
Fox News via Yahoo News· 2 days agoPharmaceutical giant Cencora has notified people that private medical information, including health...
Gateway - Quartz
Quartz· 1 day agoModerna stock rose after new data suggested that its experimental vaccine could be used to treat a variety of cancers. The American Society of Health-System Pharmacists said the number of ongoing ...
Psoriatic Arthritis Drugs Comparably Improve Joint Outcomes
Medscape· 10 hours agoReal-world study data suggest there is little difference among five drug classes commonly used to treat PsA in terms of their ability to improve both joint and skin symptoms.
Psoriasis: Features That May Affect Biologic Rx Outcomes
Medscape· 1 day agoSeveral clinical characteristics were negatively associated with responses to biologics in a...
New JAK 1 Inhibitor Proves Promising in Phase 3 RA Trial
Medscape· 10 hours ago"This is the first highly selective JAK inhibitor originally developed, and a phase 3 clinical trial...
Cancer-fighting biotech startup InduPro raises $85M round - Puget Sound Business Journal
The Business Journals· 5 days agoInduPro Inc., a biotech company dual-headquartered in Seattle and Cambridge, Massachusetts, has...
Erasca (NASDAQ:ERAS) vs. Ascendis Pharma A/S (NASDAQ:ASND) Head-To-Head Contrast
ETF DAILY NEWS· 6 days agoErasca (NASDAQ:ERAS – Get Free Report) and Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses ...